CDMO Neuland Labs Expects Commercial Production Facility to Be Operational by Summer

With GLP-1 manufacturing consuming a growing share of global peptide capacity, Neuland is targeting innovator and emerging biotech programs facing tightening access to clinical and commercial manufacturing facilities.The post CDMO Neuland Labs Expects Commercial Production Facility to Be Operational by Summer appeared first on GEN - Genetic Engineering and Biotechnology News.